Phase 2Withdrawn
Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19
Pilot Study Into the Use of Metformin and Low Dose Naltrexone (LDN) for Patients With Coronavirus Disease 2019 (COVID-19) - Assessment of Short and Long Term Effects
- Sponsor
- AgelessRx (Industry)
- Conditions
- Covid19
- Interventions
- Metformin; Naltrexone
- Ages
- adults, older adults
- Registry
- NCT04604678
From the registry
Study into the effects of daily use of metformin and low-dose naltrexone (LDN) for 4 weeks to reduce symptoms, disease severity, and recovery time from COVID-19.
Primary outcomes
- Reduction of COVID-19 symptoms after 1 week of treatment with metformin and LDN
- Reduction of COVID-19 symptoms after 2 weeks of treatment with metformin and LDN